ONCOLYTICS CONCLUDES PATIENT TREATMENT IN RECURRENT MALIGNANT GLIOMA TRIAL

Oncolytics Biotech has completed patient treatment in its Phase I clinical trial investigating the use of Reolysin to treat patients with recurrent malignant glioma. A total of twelve patients were treated in the study, at three dosing levels. A maximum tolerated dose was not reached over this dosage range, and Reolysin appears to have been well-tolerated by the patients.

Determination of the safety of Reolysin was the primary purpose of the study. The study examined the use of a single, intratumoural injection of the drug, delivered using imaging-guided surgery, in patients with malignant gliomas that had recurred despite other treatments, including surgery and radiation therapy. After treatment with Reolysin, the Phase I patients are monitored and evaluated for safety for a period of six months.